Nuvation Bio: Na-update ang median DOR ng IBTROZI (taletrectinib) sa 50 buwan

Ang data cutoff noong Agosto 2025 ay nagpapakita na ang median duration of response ay tumaas sa 50 buwan sa mga pasyenteng TKI-naïve, na sumusuporta sa planong supplemental NDA filing sa pagtatapos ng 2025. Pinatitibay nito ang clinical profile para sa IBTROZI na naaprubahan na para sa advanced ROS1+ NSCLC.

Mahahalagang fact

Na-file: Nob 17, 2025, 10:31 PM
Kaganapan: Update sa FDA label
Direksyon: Positibo
Kumpanya: NUVBNuvation Bio
Asset: taletrectinib
Pinagmulan: SEC 8-K
Kumpiyansa: May source
cORR: 89% (pinagsama)
mPFS: 46 buwan
Gitnang DOR: 50 buwan

Sipi mula sa source

EX-99.1 2 d845081dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 DRIVEN BY SCIENCE FOCUSED ON LIFE November 2025 Forward-looking statements Certain statements included in this presentation (this “Presentation”) that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are no

SEC 8-K